AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ALLIANCE PHARMA PLC

Pre-Annual General Meeting Information May 22, 2013

7478_agm-r_2013-05-22_718ff366-dd98-4dc5-96fa-1179691a67d4.html

Pre-Annual General Meeting Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2626F

Alliance Pharma PLC

22 May 2013

For immediate release 22 May 2013

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

AGM Statement

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold its Annual General Meeting in London later this morning.

Michael Gatenby, the Company's Chairman, will make the following comments:

"Trading in the first four months of 2013 has been 6% ahead of the same period last year, with turnover of £15.1 million.

"HydromolTM sales continue to grow well.  There have been reduced sales of Nu-SealsTM in Ireland although measures to counteract generic competition are helping to mitigate the impact.

"Sales of the products acquired in 2012 were £1.8 million.  Adjusting for these acquired products, and for the unavailability of ImmuCystTM, sales have shown underlying growth of 5%.

"We continue to assess a number of acquisition opportunities and remain confident of bringing further transactions to completion in the near future."

For further information:

### Alliance Pharma plc ### + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
### Buchanan ### + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGMNKDDKABKDAPB

Talk to a Data Expert

Have a question? We'll get back to you promptly.